title: Is Maintenance Therapy for Everyone?
abstract: Although myeloma remains an incurable disease among majority of myeloma patients, the prognosis has significantly improved after the introduction of novel agents. While more agents are being explored for their anti-myeloma activity, the more familiar agents with a better tolerability profile have been tested in the maintenance arena. Lenalidomide and bortezomib so far have shown promise as effective maintenance agents in prolonging PFS, and also OS in some studies. The current review aims at describing the clinical data supporting various maintenance therapies and also at providing some clarity to a few concerns associated with maintenance therapies.
authors: Division of Bone Marrow Transplant, Winship Cancer Institute, Emory University, Atlanta, GA. Electronic address: anooka@emory.edu.
authors: Ajay K
authors: AK
authors: Nooka
authors: Division of Bone Marrow Transplant, Winship Cancer Institute, Emory University, Atlanta, GA.
authors: Sagar
authors: S
authors: Lonial
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000066491:Clinical Decision-Making; D019468:Disease Management; D006801:Humans; D000077269:Lenalidomide; D060046:Maintenance Chemotherapy; D058990:Molecular Targeted Therapy; D009026:Mortality; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Bortezomib; High-risk myeloma; Lenalidomide; Maintenance therapy; RVD maintenance